The RSU agreement aligns management incentives with an uplisting event, but no near-term catalyst is present. Monitor for progress toward exchange listing and any subsequent filings regarding milestone achievement.
Price Chart
Executive Summary
Oncotelic Therapeutics filed an 8-K attaching a corporate presentation (Exhibit 99.1) and a Restricted Stock Unit Agreement (Exhibit 10.1) dated July 10, 2026. The RSUs vest upon uplisting of the common stock to a national exchange by June 30, 2027, with each RSU representing one share of Series A Convertible Preferred Stock (convertible into 1,000 common shares). The filing is routine and contains no material financial data.
Key Facts
- On July 13, 2026, Oncotelic presented a corporate presentation to employees, directors, officers, and advisors.
- On July 10, 2026, the company entered into a Restricted Stock Unit Agreement with an undisclosed holder and undisclosed number of RSUs.
- Each RSU represents one share of Series A Convertible Preferred Stock, convertible into 1,000 shares of common stock.
- Vesting requires achievement of a corporate milestone: uplisting of common stock to a national securities exchange (e.g., Nasdaq or NYSE) on or before June 30, 2027, plus six months of continued service.
- If the milestone is not achieved by June 30, 2027, the RSUs automatically terminate.
Financial Impact
No financial figures disclosed; RSUs are contingent and not yet issued.
Risk Factors
- Uplisting may not occur by the deadline, causing RSUs to be forfeited.
- The RSU agreement contains placeholder amounts and holder name, indicating the grant is not yet finalized.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (OTLC) — Batch item 1 | 0001493152-26-033172 |
| Document: 0001493152-26-033172-index-headers.html | 0001493152-26-033171 |
| Document: 0001493152-26-033172-index.html | 0001493152-26-033172 |
| Document: 0001493152-26-033172.txt | 0001493152-26-033172 |
| 8-K Filing (OTLC) — Batch item 5 | 0001493152-26-033171 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 13, 2026 13d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0157 (−21.50%) |
Jul 14, 2026 14w ago | 8-K | $0.0400 $0.0200 | ▼ −50.00% | ▼ −52.79% | $0.0157 (−60.75%) |
Jun 29, 2026 17w ago | 8-K | $0.0400 $0.0245 | ▲ +38.75% | ▲ +42.59% | $0.0157 (+60.75%) |
May 5, 2026 24w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −2.06% | $0.0157 (−60.75%) |
Apr 16, 2026 27w ago | 8-K | $0.0400 $0.0360 | ▼ −10.00% | ▼ −17.05% | $0.0157 (−60.75%) |
Apr 2, 2026 29w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −14.16% | $0.0157 (−60.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers